Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers July 31, 2014
Pharmacy Choice - News - Generic Drugs - July 31, 2014

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 45     Next >>     Go To Page:

7/30/14 - Afaxys Pharmaceuticals Products Now Available Nationwide; OCs Placed on Pennsylvania Medicaid's Preferred Oral Contraceptives List
Three FDA- approved oral contraceptives from Afaxys Pharmaceuticals, a division of Afaxys, Inc., are now preferred OCs, as per a recent ruling by Pennsylvania's Medicaid system. The three Afaxys Pharmaceuticals generic contraceptives now available throughout the nation are:. Available only to the public health sector, and authorized, non-retail pre
7/30/14 - All Proposals Approved at Teva's Annual Meeting of Shareholders
Upon conclusion of the meeting, the Board of Directors issued the following statement: "We appreciate the support of Teva's shareholders in our efforts to diversify the Board and strengthen our corporate governance, including reducing the size of the Board from 15 members to 13, nominating a director with extensive global pharmaceutical experience,
7/30/14 - HOSPIRA INC - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
Hospira is a provider of injectable pharmaceutical drugs and infusion technologies that it develops, manufactures, distributes and markets globally. Through a broad, integrated product portfolio, Hospira is uniquely positioned to Advance Wellness? by improving patient and caregiver safety while reducing healthcare costs. Hospira's portfolio of...
7/30/14 - Indonesia : SGS Life Science Services Announces Investment and New Services at Its Shanghai Facility [TendersInfo (India)]
Other new capabilities at the Shanghai site will include a dissolution lab for generic drug stability studies, a mycoplasma lab focused on the biological market, and a highly active compound testing laboratory to meet growing market demand. The investment in the Shanghai facility, and the increased and enhanced service offerings that will result, a
7/30/14 - InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada
As the developer of this generic injectable drug, InnoPharma has entered into an agreement with Sandoz Canada Inc., pursuant to which Sandoz Canada will make, use, sell, market and distribute Olanzapine Injection in Canada. We are pleased to work with our collaborator, Sandoz Canada, on the launch of this important generic drug. " On July 16, 2014,
7/30/14 - Perrigo Confirms First To File Patent Challenge For Generic Version Of Topicort Topical Spray 0.25%
Perrigo Company announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for desoximetasone topical spray 0.25% and that it has notified Taro Pharmaceuticals U.S.A., Inc., the owner of the Reference Listed Drug of its filing. On July 28, 2014, Taro filed suit against Perrigo in the United States D
7/30/14 - Sunshine Biopharma Launches Sunshine Biopharma Canada Inc., a Wholly Owned Canadian Subsidiary in Anticipation of Signing Manufacturing and... [Global Data Point]
Sunshine Biopharma anticipates that Sunshine Biopharma Canada will soon sign manufacturing, marketing, sales and distribution contracts for various pharmaceutical and biomedical products.According to various estimates, the worldwide market for generic pharmaceuticals which Sunshine Biopharma Canada is positioning itself to participate in is in...
7/30/14 - Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake
Decision Resources Group finds that the majority of surveyed pharmacy and medical directors in the United States believe that the key drivers of biosimilar market penetration will be the level of savings achievable by their managed care organizations and the expected lower cost to patients. Biosimilars first: Interviewed European payers indicate
7/29/14 - Central Europe Generic and Innovative Drugs Market 2018 Forecasts
What is the value of the generic and innovative drugs market in Poland, in Romania, Slovakia, the Czech Republic, Hungary and Bulgaria? Generic and innovative drugs market in Central Europe, comparative analysis, reimbursement policies and development forecasts for 2014-2018 is a comprehensive guide to the market and all its conditions and variable
7/29/14 - Medicines360 and Actavis Secures FDA Acceptance for Filing of NDA for Levosert IUD [Manufacturing Close - Up]
Medicines360 and Actavis reported that the U.S. Food and Drug Administration has accepted for filing Medicines360's New Drug Application for Levosert, a hormonal intrauterine contraceptive for use by women to prevent pregnancy. According to a media release, in June 2013, Medicines360 and Actavis announced that they had entered into a partnership th
Pfizer Inc. reported financial results for second-quarter 2014. At the beginning of fiscal year 2014, the company began managing its commercial operations through a new global commercial structure consisting of three operating segments: the Global Innovative Pharmaceutical segment; the Global Vaccines, Oncology and Consumer Healthcare segment; and.
7/29/14 - World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at
Using detailed company data, financial analysis, corporate strategy, and market trends analysis, GlobalData provides in-depth analysis of the current and future growth drivers of the biosimilars industry. Overview of Key Players in Global Biosimilars Market:? Hospira? Actavis? Pfizer? Sandoz? Stada Arzneimittel? Gedeon Richter? Kyowa
7/28/14 - 'This year is going to be a challenging one for US business' [DNA : Daily News & Analysis (India)]
Your first quarter numbers for US are almost flat at 9.33%. Is there any specific reason? I feel things are really slow as per FDA approvals and that is why, we are seeing slower growth.
7/28/14 - Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan
By a News Reporter-Staff News Editor at Pharma Business Week Abbott announced that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded...
7/28/14 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Animal Generic Drug User Fee Cover Sheet
SUMMARY: The Food and Drug Administration is announcing that a collection of information entitled "Animal Generic Drug User Fee Cover Sheet" has been approved by the Office of Management and Budget under the Paperwork Reduction Act of 1995.. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Col
7/28/14 - Changes in generic pill color and shape disrupt use
By a News Reporter-Staff News Editor at Cardiovascular Week Boston, MA- Generic versions of the same prescription drug are clinically interchangeable but often look different depending on the manufacturer. Studying a national cohort of patients who recently suffered a heart attack, researchers from Brigham and Women's Hospital have found that var
7/28/14 - Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 Investigational Etanercept Biosimilar In Chronic Plaque Psoriasis RaPsOdy
By a News Reporter-Staff News Editor at Biotech Business Week Coherus BioSciences>, Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept, in chronic plaque psoriasis. "It represents a pivotal study in the global clinical development for CHS-0214 and, if positive, will provide supp
7/28/14 - Depomed Announces District Court Order in ANDA Litigation
By a News Reporter-Staff News Editor at Pharma Business Week Depomed, Inc. announced that on July 17, 2014, Judge Joel A. Pisano of the United States District Court for the District of New Jersey entered an order preliminarily enjoining Actavis Elizabeth LLC and Actavis Inc. from marketing a generic version of Gralise prior to the Court's issu
7/28/14 - Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries
Release date- 25072014- MELBOURNE, Australia- Gilead Sciences, Inc. announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead's investigational drug tenofovir alafenamide for HIV and hepatitis B, contingent on the medicine's U.S. regulatory approval.
7/28/14 - Leading U.S. Proxy Advisory Firm Supports Teva Nominees and Other Shareholders' Meeting Proposals
By a News Reporter-Staff News Editor at Pharma Business Week Teva Pharmaceutical Industries Ltd., reported that ISS Proxy Advisory Services, the leading U.S. independent proxy advisory firm, recommended that shareholders vote in favor of all Teva nominees for director and for each of the other proposals on the agenda for consideration at the Comp
7/28/14 - Mapi Pharma postpones and halves Nasdaq IPO [Globes, Tel Aviv, Israel :: ]
July 28 Drug developer Mapi Pharma, which was scheduled to complete a $37 million financing round at the end of last week, published a revised prospectus on Friday for raising only $20 million. Mapi Pharma is not bringing a great dream to its offering, while on the other hand, it does not present a well-oiled generic operation with reliable reven
7/28/14 - New Findings from RAND in the Area of Medicare and Medicaid Described (Impact of Medicare Part D Plan Features on Use of Generic Drugs)
By a News Reporter-Staff News Editor at Managed Care Weekly Digest Fresh data on Medicare and Medicaid are presented in a new report. According to news reporting from Pittsburgh, Pennsylvania, by NewsRx journalists, research stated, "Little is known about how Medicare Part D plan features influence choice of generic versus brand drugs. Generic co
7/28/14 - Research and Markets Adds Report: The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others) [Health & Beauty Close - Up]
Research and Markets has announced the addition of the "The World Market for Biosimilars, 4th Edition" report to its offerings. In a release, Research and Markets noted that report highlights include:. -Beijing Four Rings Biopharmaceutical Co Ltd.
7/28/14 - Wockhardt's plant may soon get out of regulatory woes [DNA : Daily News & Analysis (India)]
Mumbai: Wockhardt Ltd, which denied stake-sale rumours on Friday following an unusual spurt in its stock price, is in the final stages of receiving much-awaited regulatory approvals for its Chikalthana unit in Maharashtra. When contacted by dna regarding possible audits, FDA spokesperson Christopher Kelly said, "The Wockhardt facilities that were p
7/26/14 - Biocon files first new drug applications [DNA : Daily News & Analysis (India)]
Mumbai: Bangalore- based Biocon on Friday said it has filed its first abbreviated new drug applications targeting the US generics market during the June quarter. The biotechnology company has reported a 9% increase in its net profit at Rs 102.91 crore for the quarter ended June 2014 compared with Rs 93.5 crore posted during the corresponding period
Articles(s): 1 - 25 of 45     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Lupus: What You Need to Know
This lesson is supported by:
West Virginia Best Practice Prescribing & Drug Diversion Training
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement